Long-term follow-up of intravesical abobotulinumtoxinA (Dysport®) injections in women with idiopathic detrusor overactivity

Objective:Only a few numbers of studies have been published on the use of abobotulinumtoxinA(Dysport®)in idiopathic detrusor overactivity(IDO).This study reported the long-term follow-up of women with IDO who were treated with intravesical Dysport®injections.Methods:Two hundred and thirty-six patients with IDO who had failed first-line conservative and antimuscarinic therapy received 500-900 units of Dysport®between April 2014 and July 2015.All patients were followed up for 5 years after their initial injection and interviewed on the phone.Results:A total of 236 women with IDO aged from 18 years to 84 years(mean±standard deviation:49.6±15.9 years)were included in our study.The median follow-up time for patients was 36.5(range:10-70)months,and the median recovery time after injection was 18.5(range:0-70)months.A total of 83(35.2%)patients stated that they had subjective improvement of their symptoms whereas 84(35.6%)patients did not report any improvement in symptoms.The initial International Consultation on Incontinence Questionnaire Overactive Bladder mean score was 6.9(standard deviation 3.4).There was a positive association between the median recovery time and the components of the International Consultation on Incontinence Questionnaire Overactive Bladder questionnaire.Conclusion:In a sub-population of overactive bladder patients with IDO who have failed first-line therapy,a single intravesical Dysport®injection can resolve patient symptoms completely or reduce the symptoms to an acceptable level that can be controlled with antimuscarinics or re-injection on demands.

The clinical use of interventional chemotherapy and intravesical instillation for preventing recurrence of superficial bladder cancer

Objective To study the therapeutic efficacy of combined interventional chemotherapy and intravesical instillation of mitomycin on preventing bladder cancers from recurring after local ablation. Methods 28 patients with superficial bladder cancers were randomized into combined interventional chemotherapy and intravesical instillation of mitomycin or intravesical instillation of mitomycin alone for preventing recurrence after local ablation. The result was assessed by x2 test. Results The patients have been followed up for 12-26 months (mean 21 months). 1 case has had tumor recurrence in the combined modality therapy group and 4 in the intravesical instillation alone group, the tumor recurrence rate being 7% (1/14) and 29% (4/14) respectively (P【0.05). Conclusion Combined use of interventional chemotherapy and intravesical instillation of mitomycin is effective in preventing superficial bladder cancer from recurring after local ablation with fewer adverse effects. The ragimen is not only reliable but

The effects of intravesical therapy with elemene in preventing postoperative recurrence of bladder cancer

To investigate the effects of intravesical therapy with elemene in preventing postoperative recurrence of superficial bladder cancer and its toxic and side effects.Methods This series included 123 patients with superficial bladder cancer (T1),consisting of transitional cell carcinoma GⅠ in 37 cases,GⅡ in 73 and GⅢ in 13.They all underwent surgical treatment.Postoperatively,they were randomly assigned to 2 groups;63 patients in elemene group received instillation of elemene (400 mg,once a week) 2 weeks after operation and 60 patients in mitomycin C (MMC) group received instillation of MMC (40 mg,once a week) 2 weeks after operation.The instillations were repeated for 6 weeks and thereafter monthly for 1 year.The recurrence rates,side effects,and NK cell activity before and after treatment were evaluated.Results The recurrence rate of elemene group (mean follow-up of 19.7 months) was 7.9% (5 cases),which was significantly lower than that (25.0%,15 cases) of MMC group (mean follow-up of 19.4 months;P<0.05).The side effect in elemene group (3.2%,2 cases) was significantly milder than that in MMC group (25.0%,15 cases)(P<0.05).In elemene group,the NK cell activity after treatment (28±2)% was significantly higher than that before treatment(20±2)%(P<0.05).Conclusion Instillation of elemene after operation is effective and safe in preventing postoperative recurrence of bladder cancer.8 refs.

Long-term follow-up of Ta transitional cell carcinoma of bladder after treatment of TURBt plus intravesical therapy

To stduy the association between the prognosis of Ta transitional cell carcinoma (TCC) of the bladder and risk-related factors.Methods A total of 88 cases (62 males and 26 females;mean age,61 years;age range,41-81 years) of initial T.TCC of the bladder treated with transurethral resection of bladder tumor (TURBt) plus intravesical chemotherapy or immunotherapy were enrolled.Among them,there were 26 cases of G1,61 cases of G2 and 1 case of G3.For tumor site,62 cases (16 cases of G1,45 of G2,1 of G3) had single tumor and 26 cases (10 cases of G1,16 of G2) had multi-site tumors.The mean follow-up was 113 months (range,56-168 months).The tumor grade,original tumor number and their association with the recurrence and progression of this type of TCC were retrospectively analyzed.Results The overall recurrence rate (RR) was 60% (53/88).In single tumor group,RR of G1 cases was 25% (4/16);RR of G2 cases was 62% (28/45) and the total RR was 52% (32/62).In multi-site tumor group,RR of G1 cases was 80% (8/10),RR of G2 cases was 75% (12/16) and the total RR was 77% (20/26).The RR of multi-site tumor group was significantly higher than that of single tumor group (P<0.01).In single tumor group,RR of G2 cases was significantly higher than that of G1 cases (P<0.001).In multi-site tumor group,there was no association of RR with tumor grade.There was no progression in G1 tumor cases.The progression rate was 42.5% (17/40) in G2 tumor cases;among them,30% (12/40) progressed to T1G2 tumors and 12.5% (5/40) progressed to T2G2 tumors.The RR of cases who received thiotepa,mitomycin and BCG were 75% (12/16),68% (30/44) and 40% (11/27),respectively.Tumor specific mortality was 1.14% (1/88,a T2G3 case).Conclusion The multi-site Ta TCC of the bladder has relatively higher RR and greater chance of progression after the treatment of TURBt plus intravesical chemotherapy or immunotherapy,especially in the poor differentiated tumors,thus active treatment and close follow-up are essential in clinical practice.9 refs.

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer

Objective:To compare the efficacy and safety of hyperthermic intravesical chemotherapy(HIVEC)and intravesical chemotherapy(IVEC)in patients with intermediate and high risk nonmuscle-invasive bladder cancer(NMIBC)after transurethral resection.Methods:We included 560 patients diagnosed with primary or recurrent NMIBC between April 2009 and December 2015 at 1 of 6 tertiary centers.We matched 364 intermediate or high risk cases and divided them into 2 groups:the HIVEC+IVEC group[chemohyperthermia(CHT)composed of 3 consecutive sessions followed by intravesical instillation without hyperthermia]and the IVEC group(intravesical instillation without hyperthermia).The data were recorded in the database.The primary endpoint was 2-year recurrence-free survival(RFS)in all NMIBC patients(n=364),whereas the secondary endpoints were the assessment of radical cystectomy(RC)and 5-year overall survival(OS).Results:There was a significant difference in the 2-year RFS between the two groups in all patients(n=364;HIVEC+IVEC:82.42%vs.IVEC:74.18%,P=0.038).Compared with the IVEC group,the HIVEC+IVEC group had a lower incidence of RC(P=0.0274).However,the 5-year OS was the same between the 2 groups(P=0.1434).Adverse events(AEs)occurred in 32.7%of all patients,but none of the events was serious(grades 3–4).No difference in the incidence or severity of AEs between each treatment modality was observed.Conclusions:This retrospective study showed that HIVEC+IVEC had a higher 2-year RFS and a lower incidence of RC than IVEC therapy in intermediate and high risk NMIBC patients.Both treatments were well-tolerated in a similar manner.

Patients with small prostates and low-grade intravesical prostatic protrusion e A urodynamic evaluation

Abstract Objective:Despite high-grade intravesical prostatic protrusion(IPP)being closely related to bladder outlet obstruction(BOO),up to 21%of patients with low IPP remain obstructed.This study evaluates the characteristics and urodynamic findings of men with small prostates and low IPP.Methods:One hundred and fourteen men aged>50 years old with lower urinary tract symptoms(LUTS)were assessed with symptoms,uroflowmetry,serum prostate-specific antigen(PSA),transabdominal ultrasound measurement of prostate volume(PV),IPP and post-void residual urine(PVRU).All patients underwent pressure flow studies.Patients with PV<30 mL and IPP
10 mm were examined for parameters correlating with BOO or impaired detrusor contractility.Results:Thirty-six patients had PV<30 mL and IPP<10 mm.Nine patients(25.0%)had urodynamic BOO,all with normal bladder contractility.Fourteen patients(38.9%)had poor detrusor contractility and all had no BOO.PV,PVRU and IPP were significantly associated with BOO,with IPP showing greatest positive correlation.Both Qmax and IPP were significantly associated with detrusor contractility.At 5-year follow-up,most patients responded to medical therapy.Only three out of nine patients(33.3%)with BOO eventually underwent surgery,and all had a high bladder neck seen on the resectoscope.Only one patient(7.1%)with poor detrusor contractility eventually required surgery after repeat pressure flow study revealed BOO.Conclusion:In men with small prostates and low IPP,the presence of BOO is associated with higher PV,PVRU and IPP,and most respond well to medical management.BOO can possibly be explained by elevation of the bladder neck by a small subcervical adenoma.

Clinical value of intravesical prostatic protrusion in the evaluation and management of prostatic and other lower urinary tract diseases

Intravesical prostatic protrusion(IPP)has emerged as a new prostatic morphometric parameter of significance to aid the clinicians in various aspects of managing the patients with some diseases of the lower urinary tract and the prostate.These include but may not be limited to its role in such conditions as:bladder outlet obstruction,trial without catheter,medical treatment effect,progression of lower urinary tract symptoms related to benign prostatic hypertrophy(LUTS/BPH),risk factor for bladder stone in BPH,overactive bladder,prostate carcinoma,and early urinary continence recovery after laparoscopic radical prostatectomy.In this review,I will try to summarize the different researchers’efforts on the potential practical application of this clinical tool.Technology is ever evolving to help us in the diagnosis and management of our patients.However,we as clinicians should contemplate their cost and possible suffering for the patient by wise and judicious utilization based on our clinical experience and tools.IPP seems to be one such promising clinical tool.

An Unusual Intravesical Foreign Body for Abortion Attempt. About a Case Report at Bobo Dioulasso University Teaching Hospital (Burkina Faso) and Literature Review

We reported a case of an intravesical foreign body in a 16 years old teenager for abortion attempt. During laparotomy for suspected pelvic appendicitis, we incidentally discovered an intravesical foreign body. From this first observation in our urology division, we reviewed the literature on the nature and circumstance of self introduction in bladder of foreign body and their surgical ablation. We emphasized the importance of endoscopy as a support of diagnosis and therapeutic of intravesical foreign body. This observation also highlighted the lack of information in our teenagers about reproductive and sexual health.

Low Releasing Mitomycin C Molecule Encapsulated with Chitosan Nanoparticles for Intravesical Installation

The aim of this investigation is preparation of Mitomycin-C encapsulated with chitosan nanoparticles synthesis using ionic gelation technique for intravesical controlled drug delivery systems. This study was conducted in vitro. Cumulative amount of drug released from the nanoparticles was calculated. Mitomycin-C release studies were examined for different pH values. During the drug loading and release studies, initial amount of drug was changed (i.e., 0.5, 1.25 and 2.5 mg) to get different release profiles and the release studies were repeated (n = 6). The loading efficiencies of Mitomycin-C with three different initial concentrations 0.5mg/ml, 1.25 mg/ml and 2.5 mg/ml into chitosan nanoparticles were 54.5%, 47.1% and 36.4%, respectively. For different pH values, the cumulative releases of Mitomycin-C from chitosan nanoparticles were 47% and 53% for pH 6.0 and 7.4, respectively (p < 0.01). For different drug doses, the cumulative releases of Mitomycin-C (MMC) from Chitosan nanoparticles were 44%, 53% and 65% for 0.5 mg/mL, 1.25 mg/mL and 2.5 mg/mL respectively (p < 0.01). The anticancer activity of Mitomycin-C loaded chitosan nanoparticles was measured in T24 bladder cancer cell line in vitro, and the results revealed that the 2.5 MMC coated Chitosan nanoparticles had better tumor cells decline activity. From this investigation, we conclude that the drug encapsulated synthesized chitosan nanoparticles possess a high ability to be used as pH and dose responsive drug delivery system. This systematic investigation demonstrates a promising future for the intravesical installation in treatment of the superficial bladder cancer.

单次灌注化疗后膀胱持续生理盐水冲洗或增加中低风险非肌层浸润性膀胱癌进展风险

目的探究行经尿道膀胱肿瘤切除术(TURBT)的中低风险非肌层浸润性膀胱癌(NMIBC)患者单次即刻膀胱灌注化疗(SIIC)后膀胱持续生理盐水冲洗(CSBI)的治疗效果。方法回顾性分析2004年1月—2019年12月于北京大学人民医院泌尿外科行TURBT的211例中低风险NMIBC患者的临床资料,根据患者SIIC后是否进行CSBI分为CSBI组和无CSBI组,比较两组患者的复发率、进展率、无复发生存率和无进展生存率。通过Cox单因素及多因素回归分析探究CSBI是否为患者肿瘤复发和进展的危险因素。结果两组患者的基线资料、复发率和进展率比较,差异均无统计学意义(P>0.05)。两组患者无复发生存率比较无明显差异,而CSBI组无进展生存率更低(χ^(2)=8.270,P=0.004)。在多因素Cox回归分析中,糖尿病(HR:2.240,95%CI:1.066~4.704,P=0.033)和多发肿瘤(HR:3.060,95%CI:1.639~5.711,P<0.001)是中低风险NMIBC患者肿瘤复发的独立危险因素,CSBI(HR:7.914,95%CI:1.710~36.632,P=0.008)是肿瘤进展的独立危险因素。结论SIIC后CSBI可能会增加中低风险NMIBC患者的进展风险,但该结论仍需要更大样本量进行验证。

Swallowing Difficulties,Oral Symptoms,and Nutrition in Long-Term Care Elderly Residents-A Secondary Publication

Oral health is often impaired in people living in residential care.In older people,poor oral health is associated with functional deficits,multiple sclerosis,and memory disorders.Keeping one’s teeth healthy throughout life would promote both oral health and general health.Biting and swallowing problems in older people are also linked to oral health,limiting eating activities and requiring diet changes to softer foods that are easy to chew and swallow.This may limit dietary diversity and adequate nutrient intake.Although eating-related chewing and swallowing problems are common in institutionalized residents,they are often addressed too late,when the resident is already malnourished.Nutrition in nursing and retirement homes has been the subject of various studies since the 2000s.However,studies on swallowing and chewing difficulties are scarce and their link to adequate nutrient intake has received lesser attention[6,7].

膀胱癌病人疾病进展恐惧、生活质量的相关性研究

目的:调查卡介苗维持膀胱灌注病人疾病进展恐惧、生活质量水平,探索其相关关系。方法:采用便利抽样法选取2017年5月-2020年5月于医院泌尿外科进行卡介苗维持膀胱灌注的267例膀胱癌病人为研究对象,收集一般资料,采用中文版疾病进展恐惧简化量表(FOP-Q-SF)、第4版FACT-G量表测量病人的疾病进展恐惧、生活质量水平,分析、探索两者的相关性。结果:维持膀胱灌注病人疾病进展恐惧(24.40±5.61)分,其中生理健康(12.01±4.60)分、社会家庭(12.38±5.03)分,17例总得分>34分,占比6.41%;生活质量(88.27±12.14)分,其中躯体症状(10.99±4.06)分、社会/家庭状况(23.74±7.92)分、心理状况(11.26±3.98)分、功能状况(22.36±7.99)分、膀胱癌特异性模块(19.93±5.10)分;Pearson相关分析得出两者呈负相关(r=-0.367,P<0.01),病人疾病进展恐惧感越强烈,生活质量越差。结论:维持膀胱灌注病人存在疾病进展恐惧,与生活质量呈负相关,应重点关注病人疾病进展恐惧水平,制定相应干预措施和健康教育方法,提高病人生活质量。

高危非肌层浸润性膀胱癌术后行膀胱热灌注化疗和卡介苗灌注治疗的对比研究

目的:探讨膀胱热灌注化疗和卡介苗(BCG)膀胱灌注预防高危非肌层浸润性膀胱癌患者术后复发的安全性和有效性。方法:回顾性分析2019年8月—2021年8月在新乡医学院第一附属医院行经尿道膀胱肿瘤电切术,且术后行吉西他滨膀胱热灌注化疗(HIVEC-GEM)或BCG膀胱灌注的高危非肌层浸润性膀胱癌患者资料共74例,其中38例行HIVEC-GEM膀胱灌注(HIVEC-GEM组),36例行BCG膀胱灌注(BCG组),比较两组术后肿瘤复发率和进展率以及不良反应发生率。结果:两组术后6个月的复发率(5.26%vs.2.78%,χ^(2)=0.002)和进展率(5.26%vs.2.78%,χ^(2)=0.002)、术后12个月的复发率(13.16%vs.8.33%,χ^(2)=0.086)和进展率(10.53%vs.8.33%,χ^(2)=0.006)以及术后24个月的复发率(18.42%vs.13.89%,χ^(2)=0.279)和进展率(13.16%vs.11.11%,χ^(2)=0.007)差异均无统计学意义(均P>0.05),多种不良反应发生率之间的比较也无统计学意义(均P>0.05)。结论:HIVEC-GEM的疗效和安全性与BCG膀胱灌注相当。

非肌层浸润性膀胱癌新型腔内治疗研究进展

膀胱癌是最常见的泌尿系肿瘤之一,约70%的患者在初次诊断时为非肌层浸润性膀胱癌(NMIBC),然而其在5年内复发率高达31%~78%,且17%~45%的患者会在后续发展为肌层浸润性膀胱癌(MIBC)。目前,传统的化学药物和卡介苗(BCG)灌注治疗已经不能满足临床需要。近年来,新型腔内疗法包括各种免疫基因疗法、光动力治疗以及新型药械组合已投入应用,本文将综述这些最新方法的研究进展,为临床NMIBC的治疗提供新的方向。

膀胱内灌注卡介苗致多器官功能衰竭1例分析

目的关注膀胱灌注卡介苗后引起的并发症,探讨发病机制,为临床应用提供参考。方法分析膀胱内灌注卡介苗致多器官功能衰竭的病例,查阅文献对此并发症发病率、发病机制、临床表现等进行讨论。结果该患者经升压、经验性抗感染、抗休克、抗结核、补液等对症治疗后,实验室指标回升,病情好转出院。但患者仍不能排除播散性结核感染的可能,过敏反应也有可能参与其中。结论虽然大部分患者对膀胱灌注卡介苗耐受性良好,但仍需警惕其发生脓毒血症的可能。

经直肠超声测量膀胱内前列腺突出程度对临床有意义前列腺癌检出率的价值

目的:探讨经直肠超声(TRUS)测量膀胱内前列腺突出程度(IPP)对临床有意义前列腺癌(CsPCa)检出率的价值。方法:回顾性分析2019年1月至2022年12月在东部战区总医院和江苏省人民医院经TRUS引导下行前列腺穿刺活检的患者128例。TRUS测量IPP大小并进行分级(0~3级),比较Gleason评分<7分(对照组)和Gleason评分≥7分(CsPCa组)患者临床病理及超声影像特征的差异及相关性。使用多元Logistic回归分析筛选与CsPCa检出率相关的因素。结果:单因素分析结果显示CsPCa组患者前列腺体积显著大于对照组[(51.3±12.1)ml vs(43.2±11.3)ml,P<0.05],PSAD显著低于对照组[(0.45±1.92)ng/ml vs(0.59±2.14)ng/ml,P<0.05]。CsPCa在IPP 3级的患者中占比低于IPP 0~2级(56.0%vs 85.4%、87.1%、80.6%),差异具有统计学意义(P<0.05)。Spearman相关分析结果表明,Gleason评分与前列腺体积呈正相关(r=0.612),与PSAD(r=-0.735)以及IPP分级(r=-0.619)呈负相关(P<0.05)。通过Logistic回归分析结果显示IPP 3级(OR 0.690,95%CI0.380~0.995,P=0.032)为CsPCa的独立保护因素。结论:CsPCa与前列腺IPP分级具有显著相关性,与IPP 0~2级患者相比,IPP 3级患者经TRUS引导下穿刺活检CsPCa检出率降低。因此,IPP分级增高时需警惕假阴性率的发生。

吉西他滨膀胱灌注化疗在非肌层浸润性膀胱癌术后患者中的应用效果

目的探讨吉西他滨膀胱灌注化疗在非肌层浸润性膀胱癌术后患者中的应用效果。方法根据治疗方法的不同将120例非肌层浸润性膀胱癌患者分为对照组和观察组,每组60例。所有患者均进行手术治疗,对照组患者术后给予吡柔比星膀胱灌注化疗,观察组患者术后给予吉西他滨膀胱灌注化疗。比较两组患者的临床疗效、肿瘤标志物[血清癌胚抗原(CEA)、尿纤维蛋白原降解产物(FDP)]水平、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]及不良反应发生情况。结果观察组患者的疾病控制率为88.33%,明显高于对照组患者的68.33%,差异有统计学意义(P﹤0.01)。治疗后,两组患者血清CEA、尿FDP水平均低于本组治疗前,观察组患者血清CEA、尿FDP水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者躯体功能、角色功能、社会功能、总体健康评分均高于本组治疗前,观察组患者躯体功能、角色功能、社会功能、总体健康评分均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论吉西他滨膀胱灌注化疗可提高非肌层浸润性膀胱癌术后患者的临床疗效和生活质量,降低肿瘤标志物水平,且安全性良好。

前列腺突入膀胱程度及尿TIMP-2水平与前列腺增生患者膀胱出口梗阻严重程度的相关性分析

目的研究前列腺突入膀胱程度(Intravesical prostatic protrusion,IPP)及尿金属蛋白酶组织抑制剂-2(Tissue inhibitor of metalloproteinase-2,TIMP-2)与前列腺增生患者膀胱出口梗阻(Bladder outlet obstruction,BOO)严重程度的相关性。方法收集99例良性前列腺增生(Benign prostatic hyperplasia,BPH)患者纳入本研究,收集患者临床资料,检测患者IPP及尿TIMP-2,对患者进行尿动力学检测。根据国际前列腺症状评分(International prostate symptom score,IPSS)将患者分为3组,0~7评分为轻度组,共42例,8~19分为中度组,共25例,20~35分为重度组,共32例。采用Logistic回归分析3组患者的临床资料、IPP、尿TIMP-2、膀胱出口梗阻指数(Bladder outlet obstruction,BOOI)的相关性。采用受试者工作特征曲线(Receiver operating characteristic,ROC)分析IPP、TIMP-2检测预测BOO的敏感性。结果使用单因素方差分析法分析3组患者的临床指标,随着患病程度加重,年龄、TPV、IPSS、IPP、尿TIMP-2水平均有增加趋势,尿动力学指标中Qmax下降,Pdet.Qmax、BOOI、PVR均升高,且差异具有统计学意义(P均<0.05)。相关性分析结果显示,3组患者BOOI与年龄、BMI、TPV、PVR无显著相关性(P均>0.05)。轻度组、中度组和重度组患者BOOI与IPP、尿TIMP-2以及IPSS均呈正相关(P均<0.05)。ROC曲线分析显示IPP与尿TIMP-2单独预测BOO均具有较强敏感性,IPP联合尿TIMP-2检测敏感性更高(P均<0.05)。结论IPP、尿TIMP-2与前列腺增生患者BOO严重程度具有相关性,且IPP联合尿TIMP-2预测BOO具有较高敏感性。

Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence

Background Superficial bladder cancer accounts for 60%-70% of all bladder cancer cases in China, when treatment consists of only transurethral resection of the bladder tumor （TUR-BT）, recurrence and progresses in the bladder are observed in some patients. There are numerous reports of trials of intravesical instillation of anticancer agents with the objective of lowering this recurrence rate. The aim of this study was to compare the prophylactic efficacy and safety of epirubicin （EPI）, pirarubicin （THP） and hydroxycamptothecin （HCPT） in superficial bladder cancer.Methods This study enrolled a total of 189 patients who had been diagnosed with superficial bladder cancer during the period from 2004 through 2007 at Beijing Friendship Hospital. All patients were randomly allocated to one of three treatment groups. Patients in group A received 29 doses of EPI 30 mg/30 ml, patients in group B received 29 doses of THP 30 mg/30 ml, and patients in group C received 29 doses of HCPT 30 mg/30 ml, over a period of 24 months.Results The recurrence-free rate in the 2 anthracycline treatment groups （A and B） were significantly better than that of the HCPT treatment group. In the safety evaluation, the incidences of pollakiuria, pain on urination, dysuria, hematuria,and contracted bladder were not significantly different between groups A and B, but some were significantly higher in groups A and B than that in group C.Conclusion The efficacy of EPI and THP was significantly better than HCPT in the prevention of bladder cancer recurrence.

术前血清FOXO1、FABP4水平与非肌层浸润性膀胱癌患者经尿道膀胱肿瘤切除术后灌注治疗疗效的相关性分析

目的:探讨术前血清叉头框蛋白O1(Fork head box protein O1,FoxO1)和脂肪酸转运蛋白4(fatty acid-binding protein 4,FABP4)与非肌层浸润性膀胱癌(Non-muscle invasive bladder cancer,NMIBC)患者灌注治疗疗效的关系。方法:选取2021年1月至2022年10月期间本院收治的68例NMIBC患者作为研究对象。所有患者进行经尿道膀胱肿瘤切除术(Transurethral resection of bladder tumor,TURBT)治疗,患者术后给予表柔比星膀胱灌注。随访12 m,根据最终的病理结果,将患者分为复发组和未复发组。检测对比两组术前血清FOXO1水平和FABP4水平。分析术前血清FABP4水平与TURBT术后膀胱灌注疗效的相关性及诊断价值。结果:68例患者TURBT术后给予表柔比星膀胱灌注,复发率22.1%。复发组术前血清FOXO1水平与未复发组无明显差异(P>0.05);复发组术前血清FABP4水平显著高于未复发组(P<0.05)。以术前血清FABP4水平预测TURBT术后给予表柔比星膀胱灌注治疗后复发的AUC=0.7052。结论:术前血清高FABP4水平提示TURBT术后给予表柔比星膀胱灌注治疗易复发,其用来预测表柔比星膀胱灌注治疗效果有较高价值。